TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04774835

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIVST
Description: aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV self-testing by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard aPS
Description: aPS will be offered to sexually active men and women who test HIV seropositive at the study sites by facility staff supported by aPS advisors. Those accepting aPS will be asked to provide names and contact information (phone numbers; home and work addresses) for their sexual partners, and these partners will be contacted, notified anonymously of the HIV exposure, and offered HIV testing at their local HTS location by HTS counselors working at the facilities. Any partner who tests HIV seropositive will receive assistance linking to care and registering in an HIV comprehensive care clinic. They will also receive aPS so that their partners can be notified and HIV tested. Follow-up of index clients will continue after testing through HTS locations and all partners will be followed to determine HIV testing and treatment outcomes.
Study: NCT06355778

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit. During the MRI the participants will complete various tasks.

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit. During the MRI the participants will complete various tasks.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computer Tasks
Description: Eligible participants will complete computer tasks (cognitive tasks, spatial navigation tasks, context dependent fear learning, etc.) at visit 1 and then during the MRI.
Study: NCT06044688

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EyeQue VisionCheck
Description: Automated subjective refraction system provides estimates of sphere, cylinder, and axis measurements of the eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoropter
Description: Standard of care, ophthalmic testing device, used by eye care professionals to measure the refractive error of the eye and determine prescription.
Study: NCT05667714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA58 Nasal Spray
Description: SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA58 Nasal Spray
Description: SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided by Sinovac Life Sciences Co. , Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided by Sinovac Life Sciences Co. , Ltd.
Study: NCT05070221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)
Description: less than 8mL/time，Q2W，i.t.；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)
Description: less than 8mL/time，Q2W，i.t.；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody for injection
Description: 200mg/time，Q3W，i.v.；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody for injection
Description: 200mg/time，Q3W，i.v.；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg，bid，p.o.；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5mg，bid，p.o.；
Study: NCT05656924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital prosthetic interface technology
Description: Individuals randomized to this group will receive a socket and liner that are manufactured using a novel technique meant to achieve a better distribution of pressure on the residuum. The study is based on the hypothesis that an improvement in pressure distribution on the residuum will enable high adherence to an exercise program meant to improve health status in dysvascular amputees.
Study: NCT05564065

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency thermocoagulation of sensory branches of hip joint
Description: There are two main nerves that carry the pain sensation of the hip joint. These nerves are the femoral and obturator nerves. The sensory branches of these nerves going to the hip joint will be detected with a radiofrequency device under fluoroscopy and percutaneous ablation will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular steroid injection of hip joint
Description: Fluoroscopy guided percutaneous intra articular steroid injection of hip joint will be performed
Study: NCT06463613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STR Skin Tag Removal device with diary and follow-up
Description: The Investigator will assign an STR version for use, stratifying the number of skin tags in each pool. The investigator will review the subject's skin tags and agree with the subject on the body location and skin tag that will be treated as well as whether the micro or standard size of the study device is appropriate. The Investigator will also verify that the skin tag does not present implications of cancerous tissue. After informed consent and reviewing device labeling, the subject will then have the band(s) placed on the skin tag(s) by the healthcare professional. Once the band has been placed, the Investigator will examine the skin tag, complete study documentation. The subject will then review trial diary instructions, including but not limited to the documentation of all observable characteristics regarding the banded skin tag(s). This diary is electronic (eDiary) and accessed through a secure website and must be fully completed to successfully finish the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STR Skin Tag Removal device with diary and follow-up
Description: The Investigator will assign an STR version for use, stratifying the number of skin tags in each pool. The investigator will review the subject's skin tags and agree with the subject on the body location and skin tag that will be treated as well as whether the micro or standard size of the study device is appropriate. The Investigator will also verify that the skin tag does not present implications of cancerous tissue. After informed consent and reviewing device labeling, the subject will then have the band(s) placed on the skin tag(s) by the healthcare professional. Once the band has been placed, the Investigator will examine the skin tag, complete study documentation. The subject will then review trial diary instructions, including but not limited to the documentation of all observable characteristics regarding the banded skin tag(s). This diary is electronic (eDiary) and accessed through a secure website and must be fully completed to successfully finish the study.
Study: NCT05913414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: Patients receive Iron isomaltoside after IC and CCRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polysaccharide Iron Complex Pill
Description: Patients receive Polysaccharide Iron Complex Pill after IC and CCRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: All patients received intensity-modulated radiotherapy before enrolled.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: All patients received intensity-modulated radiotherapy before enrolled.
Study: NCT06437678

Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Irinotecan Hydrochloride
Description: Liposomal Irinotecan Hydrochloride Injection (Ⅱ) 56.5mg/m2 every 2 weeks
Study: NCT06020456

Intervention type: DRUG
Intervention: Desmopressin
Description: For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels

Intervention type: DRUG
Intervention: Desmopressin
Description: For the 2 groups, all patients have received an intravenous DDAVP 0,3-0,4 µg/Kg infusion associated with pre/post-desmopressin measurements of plasma FVIII levels
Study: NCT05985031

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tendon tap
Description: While examining the T reflex, the ankle was held passively in neutral, dorsiflexion and plantar flexion positions by the investigator.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tendon tap
Description: While examining the T reflex, the ankle was held passively in neutral, dorsiflexion and plantar flexion positions by the investigator.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tibial nerve stimulation
Description: H-reflex responses were examined by tibial nerve stimulation

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tibial nerve stimulation
Description: H-reflex responses were examined by tibial nerve stimulation
Study: NCT05026307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of pterygium
Description: Simple surgical excision of pterygium with bare sclera
Study: NCT05395065

Intervention type: DEVICE
Intervention: Silver Diamine Fluoride/Sodium Fluoride Varnish
Description: Application of dental caries arresting topical medication
Study: NCT04742088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ankleSOFT100
Description: During the first two weeks of follow-up, the subject shall not use the device during the sports sessions. The subject shall use the device during the sports sessions for the next 4 weeks (6 weeks of follow-up)
Study: NCT05138081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF stretching
Description: Neck flexion pattern The therapist slightly pulled the chin so that it was lifted and causing the neck to extend. Commands such as pull your chin in and look at your left hip were given to the patient. Resistance was given against left rotation, flexion and lateral flexion along with the traction to the patient's chin.Neck extension pattern The therapists lightly pulled the chin so that the neck was flexed; head was rotated and tilted to the left. Commands such as lift your chin and then lift your head to look above were given to the patient. Passive resistance was provided against right rotation, extension and lateral flexion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization
Description: Stabilization exercises are shoulder rolls, shrugging, chin tuck, scapular retraction, cervical extension. This was done for 15 repetition
Study: NCT06475014

Intervention type: PROCEDURE
Intervention: Total knee replacement
Description: Mechanical Alignment Using PSI Pre and post-operative CT Scan
Study: NCT06131879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Biostimulation of temporalis and masseter muscles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified physical therapy
Description: Progressive muscle relaxation of temporalis and masseter muscles
Study: NCT05292105

Intervention type: DEVICE
Intervention: NC Xperience
Description: Coronary dilatation balloon catheter (non compliant)
Study: NCT05867771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1022
Description: PM1022 Injection
Study: NCT05965284

Intervention type: DRUG
Group type: OTHER
Intervention: Azathioprine
Description: All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months
Study: NCT06437808

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Training with Portable Force Plates Integration
Description: This group will undergo football training sessions that incorporate the use of portable force plates. These devices will measure ground reaction forces and provide real-time data on players' movements, balance, and pressure points. The data collected will be used to create personalized training programs aimed at optimizing performance and reducing the risk of injuries.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Training
Description: This group will continue with the existing football training regimen without the use of portable force plates. Training will follow the traditional methods used at the Multan Sports Complex, focusing on physical conditioning, technical skills, and tactical awareness without the advanced biomechanical analysis provided by the force plates.
Study: NCT05875259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1
Description: Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1
Description: Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1
Description: Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1
Description: Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1
Description: Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1
Description: Treatment group A : One tablet of BR1019-1 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-2
Description: Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-2
Description: Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-2
Description: Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-2
Description: Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-2
Description: Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-2
Description: Treatment group B : One tablet of BR1019-2 administered alone once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1 + BR1019-2
Description: Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1 + BR1019-2
Description: Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
Study: NCT06355778

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computer Tasks
Description: Eligible participants will complete computer tasks (cognitive tasks, spatial navigation tasks, context dependent fear learning, etc.) at visit 1 and then during the MRI.
Study: NCT05875259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1 + BR1019-2
Description: Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1 + BR1019-2
Description: Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1 + BR1019-2
Description: Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1019-1 + BR1019-2
Description: Treatment group C : One tablet each of BR1019-1 and BR1019-2 administered in combination once daily for 7 days.
Study: NCT05919979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 34-hour fasting in sedentary conditions
Description: Participants will fast for 34h after a standardized breakfast, refraining from physical activity.
Study: NCT06771739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Support
Description: Receive $1000 preloaded cash card

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support
Description: Receive $100 preloaded cash card

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06771180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dara-CyBorD
Description: Dara-CyBorD will be used for newly diagnosed PGNMID, OR LCPT, OR TMA OR CGGN.
Study: NCT05919979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 34-hour fasting in sedentary conditions
Description: Participants will fast for 34h after a standardized breakfast, refraining from physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 34-hour fasting with high-intensity exercise
Description: Participants will fast for 34h after a standardized breakfast, performing a high-intensity exercise session 6-10 hours aprox. after starting the fasting period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 34-hour fasting with high-intensity exercise
Description: Participants will fast for 34h after a standardized breakfast, performing a high-intensity exercise session 6-10 hours aprox. after starting the fasting period.
Study: NCT06190171

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active respiratory muscle strength training
Description: Devices will be set to 60% of participants' maximum expiratory pressure and maximum inspiratory pressure. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory muscle strength training (a total of 50 repetitions).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham respiratory muscle strength training
Description: Springs will be removed from devices to ensure training is done without resistance. Participants will complete training 7 days per week by performing 5 sets of 5 repetitions for both expiratory and inspiratory sham muscle strength training (a total of 50 repetitions).
Study: NCT04482335

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06494189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 30mg PO QD

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose radiotherapy
Description: The phase Ia clinical trial took low dose radiotherapy doses of 2Gy/1f (on day 1) for group 1, 4Gy/2f (from days 1 to 2) for group 2, and 10Gy/5f (from days 1 to 5) for group 3. The radiotherapy doses in phase Ib were judged according to the efficacy and toxicity of phase Ia.
Study: NCT05860062

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Patients with prophylactic treatment (amitriptyline, topiramate) + 0.266 mg of calcifediol (15,960 IU of vitamin D)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients with prophylactic treatment (amitriptyline, topiramate) + 0.266 mg of calcifediol (15,960 IU of vitamin D)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: 3: Patients with prophylactic treatment (amitriptyline, topiramate) + and Calcium: 1 Tablet every 24 hours containing: Calcium Carbonate 300 mg + Calcium Lactate Gluconate 2.94 g (500 mg of calcium).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium
Description: 3: Patients with prophylactic treatment (amitriptyline, topiramate) + and Calcium: 1 Tablet every 24 hours containing: Calcium Carbonate 300 mg + Calcium Lactate Gluconate 2.94 g (500 mg of calcium).
Study: NCT05938192

Intervention type: PROCEDURE
Intervention: LASER surgery
Description: Patients will have laser surgery for managing HPV-related lesions
Study: NCT06409676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocols
Description: Enhanced Recovery After Surgery (ERAS) guidelines are evidence-based recommendations aimed at improving patient outcomes and reducing complications after surgery.
Study: NCT01437020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH708980 Anti-IL-10 monoclonal
Description: Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome
Description: Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.